Biolevate, a Paris-based company, has recently secured €6 million in Seed funding to support medical writers in keeping up with the documentation required for the development of new drugs. The platform developed by Biolevate aims to assist medical writers by utilizing Natural Language Processing (NLP) and visual document reading to streamline the writing process.
CEO Joel Belafa and COO Nathan Chen, who have been friends for 25 years, founded Biolevate out of a shared frustration with the slow and challenging processes involved in research and market access for therapeutic products. Despite the advancements in AI that are helping to accelerate drug development, the biotech industry still faces challenges in documenting these processes efficiently.
Belafa, with expertise in AI for enterprises, and Chen, with experience in pharmaceutical processes, combined their knowledge to create the platform named Elise. The addition of Anas Laaroussi as CTO and Antoine De Torcy as CPO further strengthened the team and their capabilities in optimizing research and compliance document management.
The platform developed by Biolevate has been recognized for its innovative approach and has been included in Station F’s Future 40 list. By leveraging NLP and Computer Vision technologies, the platform serves as an AI assistant to medical writers, guiding them through the documentation process and reducing the time and effort required to create accurate and compliant documents.
Julien Hobeika, Partner at EQT Ventures, commended Biolevate for offering an efficient solution to enhance medical writing processes using AI. He highlighted the potential of Biolevate’s platform to revolutionize medical documentation procedures, supporting innovation and driving scientific breakthroughs for the benefit of society.
In the event that the current strategy does not meet expectations, Belafa mentioned potential alternative paths for the company, including commercializing the platform as a service for other industries, selling individual models as an API, or offering drug discovery professional services.
Overall, Biolevate’s successful funding round signifies a growing recognition of the importance of efficient medical writing processes in the biotech industry. With the support of AI technologies, Biolevate is poised to make significant contributions to streamlining documentation procedures and advancing scientific research in the field of drug development.
